Metaphore Biotechnologies
PrivateLast Round
Early Funding
Apr 5, 2026
Total Funding Raised
$50M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Metaphore Biotechnologies operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was an Early Funding round in April 2026.
Metaphore Biotechnologies is a biotechnology company that utilizes its proprietary MIMIC™ platform to design functional antibodies and therapeutic molecules based on biological dynamics and biomimicry.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Metaphore Biotechnologies Comparables
Compare Metaphore Biotechnologies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Nabla Bio | 84% | |
| Valo Health | 78% | |
| Generate Biomedicines | 77% |
For institutional investors. Book with your work email.
Metaphore Biotechnologies Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Apr 5, 2026 | ||||
| Series A | May 16, 2023 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Metaphore Biotechnologies Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Global Brain Corporation | Early Funding |
| Flagship Pioneering | Early Funding, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 5, 2026
Raised capital from Flagship Pioneering and Novo Nordisk.
- Oct 15, 2025
$600M collaboration to develop obesity therapeutics.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingOct 29, 2026
Metaphore is developing an antibody discovery platform designed to address complex biological mechanisms associated with metabolic and immunological diseases on Oct 29th '26.
- hiresOct 26, 2026
Metaphore appoints Pascal Deschatelets, Ph.D., as an independent director to its board in Massachusetts on Oct 29th '26 as it prepares to advance its therapeutic programs into clinical development.
- hiresOct 26, 2026
Metaphore appoints Frank D'Amelio and Pascal Deschatelets, Ph.D., as independent directors to its board in Massachusetts on Oct 29th '26, as it prepares to advance its therapeutic programs into clinical development.
For institutional investors. Book with your work email.
Metaphore Biotechnologies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Metaphore Biotechnologies's valuation, stock price, and market status.
Is Metaphore Biotechnologies a public or private company?
Metaphore Biotechnologies is a private company.
What is the current stock price of Metaphore Biotechnologies?
Metaphore Biotechnologies is a private company, so its shares have no public market price. Caplight tracks Metaphore Biotechnologies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Metaphore Biotechnologies worth (valuation)?
Valuation information for Metaphore Biotechnologies is not publicly available.
Can I buy Metaphore Biotechnologies stock?
Metaphore Biotechnologies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Metaphore Biotechnologies's last funding round?
Metaphore Biotechnologies's most recent funding round was Early Funding on April 5, 2026.
Who are the main investors in Metaphore Biotechnologies?
Key investors in Metaphore Biotechnologies include Global Brain Corporation, Flagship Pioneering.
Will Metaphore Biotechnologies IPO soon?
No public IPO plans have been announced for Metaphore Biotechnologies.
How can I track Metaphore Biotechnologies secondary market activity?
Caplight tracks bids, offers, and trades in Metaphore Biotechnologies's shares on secondary markets.